View source for 18224865. GENERATION OF ANTI-TUMOR T CELLS simplified abstract (DANA-FARBER CANCER INSTITUTE, INC.)

=GENERATION OF ANTI-TUMOR T CELLS=


==Organization Name==

[[:Category:DANA-FARBER CANCER INSTITUTE, INC.|DANA-FARBER CANCER INSTITUTE, INC.]]


[[Category:DANA-FARBER CANCER INSTITUTE, INC.]]

==Inventor(s)==

[[:Category:Catherine J. Wu of Brookline MA (US)|Catherine J. Wu of Brookline MA (US)]][[Category:Catherine J. Wu of Brookline MA (US)]]

[[:Category:Giacomo Oliveira of Boston MA (US)|Giacomo Oliveira of Boston MA (US)]][[Category:Giacomo Oliveira of Boston MA (US)]]

==GENERATION OF ANTI-TUMOR T CELLS - A simplified explanation of the abstract==


This abstract first appeared for US patent application 18224865 titled 'GENERATION OF ANTI-TUMOR T CELLS

==Simplified Explanation==

The patent application focuses on methods for identifying expanded, exhausted, and tumor-specific T-cell clonotypes for adoptive cell transfer, as well as methods of cancer treatment and modified T cells with anti-tumor T cell receptors (TCRs).

* Methods for identifying expanded, exhausted, and tumor-specific T-cell clonotypes for adoptive cell transfer.
* Methods of cancer treatment using modified T cells with anti-tumor TCRs.

== Potential Applications ==
The technology can be applied in the field of cancer immunotherapy for developing personalized treatments based on tumor-specific T-cell clonotypes.

== Problems Solved ==
This technology addresses the challenge of identifying and targeting specific T-cell clonotypes that are effective against tumors, potentially improving the success rate of adoptive cell transfer therapies.

== Benefits ==
- Enhanced precision in targeting tumor-specific T-cell clonotypes
- Improved efficacy of cancer treatments
- Personalized approach to cancer immunotherapy

== Potential Commercial Applications ==
The technology can be utilized by biopharmaceutical companies for developing novel cancer immunotherapies with improved efficacy and personalized treatment options.

== Possible Prior Art ==
Prior art may include existing methods for identifying T-cell clonotypes in cancer immunotherapy research, as well as prior patents related to adoptive cell transfer technologies.

== Unanswered Questions ==

=== How does this technology compare to existing methods for identifying T-cell clonotypes in cancer immunotherapy? ===
The article does not provide a direct comparison to existing methods or technologies in the field.

=== What are the potential limitations or challenges associated with implementing this technology in clinical settings? ===
The article does not address any potential limitations or challenges that may arise when implementing this technology in clinical practice.


==Original Abstract Submitted==

Disclosed are methods for identifying expanded, exhausted, and tumor-specific T-cell clonotypes for adoptive cell transfer, and methods of cancer treatment and modified T cells with anti-tumor T cell receptors (TCRs).



[[Category:A61K35/17]]
[[Category:C12Q1/6881]]